MiNA Therapeutics
Activating RNA, mastering disease
Activating RNA, mastering disease
MiNA Therapeutics is a biotechnology and pharmaceutical startup based in the United Kingdom that is dedicated to activating RNA and mastering disease. Established in 2008, the company's platform harnesses an innate mechanism of gene activation to develop new medicines that restore normal function to patients' cells. MiNA Therapeutics is at the forefront of transforming the therapy landscape for severe liver and other diseases, utilizing their technology and clinical expertise to make a significant impact.
The company recently secured a $15.00M Corporate Round investment on 06 July 2021, with Eli Lilly as the lead investor, signifying a strong validation of the company's potential and the promise of its innovative approach to therapeutics. With this latest investment, MiNA Therapeutics is poised to make further strides in the development of their groundbreaking medicines and solidify their position as a key player in the biotechnology and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | $15.00M | 1 |
|
06 Jul 2021 |
| Series A | £23.00M | 1 |
|
10 Sep 2020 |
| Corporate Round | £35.00M | 1 | Sosei Group | 03 May 2017 |
No recent news or press coverage available for MiNA Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
